SCHEMBL6626490

SCHEMBL6626490

CCc1ccncc1C(=O)CCl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.43
▸ LMNA P02545 3/20 0.43
▸ HTT P42858 1/20 0.43
▸ KDM4C Q9H3R0 4/20 0.41
▸ KDM6B O15054 3/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ SIRT3 Q9NTG7 1/20 0.41
▸ CYP2E1 P05181 3/20 0.38
▸ CYP2C8 P10632 3/20 0.38
▸ CYP2D6 P10635 3/20 0.38
▸ CYP2A6 P11509 3/20 0.38
▸ CYP2B6 P20813 3/20 0.38
▸ CYP2C19 P33261 3/20 0.38
▸ MAPK1 P28482 2/20 0.37
▸ HIF1A Q16665 2/20 0.37
▸ ROCK2 O75116 1/20 0.36
▸ ROCK1 Q13464 1/20 0.36
▸ GSK3B P49841 4/20 0.35
▸ MAPT P10636 2/20 0.35
▸ KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6627674 0.88 PTGDR2 (0.42) ALDH1A1LMNAHTTKDM4CKDM6B
SCHEMBL3821293 0.82 TDP1 (0.41) ALDH1A1LMNAKDM4CKDM6BTDP1
SCHEMBL4974313 0.80 SIRT3 (0.59) ALDH1A1LMNAKDM4CKDM6BTDP1
SCHEMBL3818724 0.79 TDP1 (0.44) ALDH1A1KDM4CKDM6BTDP1SIRT3
SCHEMBL123203 0.79 KDM4C (0.51) ALDH1A1KDM4CKDM6BTDP1SIRT3
SCHEMBL30465694 0.79 KDM4C (0.51) ALDH1A1KDM4CKDM6BTDP1SIRT3
Hydrochloric Acid SCHEMBL3092651 0.79 SIRT3 (0.58) ALDH1A1LMNAKDM4CKDM6BTDP1
SCHEMBL9002466 0.78 SIRT3 (0.61) ALDH1A1HTTKDM4CKDM6BTDP1
Acetic Acid SCHEMBL16666943 0.76 KDM4C (0.49) ALDH1A1KDM4CKDM6BTDP1SIRT3
SCHEMBL6627670 0.76 SMN1; SMN2 (0.41) ALDH1A1LMNAKDM4CKDM6BTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-12-30 — — US disclosed
EP-1432706-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 — — EP disclosed
WO-2003027085-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors CYP17A1, CYP21A2, HSD17B1 ALDH1A1 88/4885LMNA 3233/4885HTT 3710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback